French Smith & Nephew CEO Olivier Bohuon seen as solid pick for top Sanofi job

Olivier Bohuon, the CEO of artificial hip and knee maker Smith & Nephew may have a leg up over other potential candidates to take the reins of drugmaker Sanofi after the firing of Christopher Viehbacher last week. He has experience in pharma and has excelled at Smith & Nephew by moving it into new markets. Most importantly, he is French.

Almirall sends 719 employees to AstraZeneca as part of respiratory deal

AstraZeneca signed on the dotted line for Almirall, gaining access to the company's promising respiratory drug portfolio and products currently under development. But now job cuts are on the horizon for Almirall, as the company is slashing jobs and sending some of its employees to AstraZeneca as part of the deal. 

Here's a first: Regeneron cuts forecast after hard-charging Eylea sales miss

Here's something Regeneron isn't used to: Cutting sales forecasts for blockbuster eye drug Eylea. But that's just what the New York biotech did Tuesday amid lower-than-expected third-quarter results.

Actavis unit yanks another 94K Bystolic bottles as recall expands

Actavis nabbed a big portfolio of branded products when it bought Forest Laboratories earlier this year. But it also inherited a quality-control problem.

Amgen-Sandoz squabble over Neupogen copy could reshape biosim marketing

The patent provisions of the Hatch-Waxman Act are familiar to both sides of the branded-generic fence by now. Not so when it comes to similar procedures related to biosimilars. In fact, as a lawsuit over Sandoz's knockoff version of the Amgen therapy Neupogen shows, the two sides don't even agree on the rules.


Which drugs win the script popularity contest? Crestor, Synthroid and Nexium

If we could see inside every medicine chest in the United States, which pill bottles or delivery devices would we see most often? Some numbers from the IMS Institute for Healthcare Informatics, reported by Medscape, tell us just that.

Allergan discloses a secret admirer looking to make an offer. Could it be ... Actavis?

Amid a heated takeover fight with Valeant, Allergan says it's got a mystery suitor. But according to The Wall Street Journal's sources, it's not all that mysterious.

Arena narrows loss as Belviq sales pick up

With a marketing push from partner Eisai behind it, Arena Pharmaceuticals more than doubled the revenue it earned from weight-loss drug Belviq in the last quarter but reported a Q3 loss of $10.7 million, or $0.05 per share.

Report: Orphan drugs to nab 19% of drug sales by 2020--if payers don't balk, that is

Pharma companies have been quick to get on board with the orphan drug development trend in recent years, racing to bring pricey treatments for small patient populations to market. And that trend won't be going out of style anytime soon, a new report says.

India's Wockhardt profit freefalls as FDA bans devastate U.S. sales

How bad can an FDA ban on plants be when the U.S. is your primary market? Really bad, India's Wockhardt found out this quarter, with its profit dropping more than $22 million, a 97% freefall.

Takeda profits fall in first half as Actos sales contract

Takeda COO Christophe Weber announced a revamped management structure in September that he is building in an effort to revive the Japanese drugmaker. And from the company's just-released 6-month earnings report, the reason the revamp is needed is apparent.

Bristol-Myers' 91-country hep C access plan still draws fire from price critics

Bristol-Myers Squibb is taking Gilead's lead when it comes to developing-world access for its hepatitis C drug, offering up a tiered pricing strategy and licensing agreements with generics makers. But according to some critics, that's not enough.

AstraZeneca seals the deal for Almirall's respiratory meds

With generic and branded rivals inching up on AstraZeneca's blockbuster respiratory drug Symbicort, the pharma giant has a game plan locked, loaded and ready to go. The company sealed the deal for Almirall's respiratory portfolio, inheriting a couple of marketed drugs to expand its current offerings and a list of medications currently under development.

Express Scripts ready to favor AbbVie hep C prospect--provided it undercuts Gilead

Express Scripts--which has made its feelings well known when it comes to the high cost of Gilead's next-gen hepatitis C drugs--says it may quickly change its preferred drug formulary to favor a anticipated challenger from the Illinois company, Reuters reports, provided it's clinically equivalent--and less expensive, of course.

Impax cuts nearly 50 employees to save money

Impax Laboratories, which has struggled for several years to get its Parkinson's drug Rytary to market, is moving away from early-stage research and has cut its R&D staff by 42 jobs, a 25% reduction to save money.

Boehringer gets NICE nod for Pradaxa for DVT/PE in U.K.

Boehringer Ingelheim has completed a trifecta of approvals for its blood thinner Pradaxa for deep vein thrombosis and pulmonary embolism. The U.K. cost watchdog NICE has now given it a thumbs up after the FDA and the European regulators did the same thing this year.

Cipla petitions India to revoke Novartis respiratory drug patents, launches low-cost version of drug

Amid growing discontent from Big Pharma companies over India's patent-busting policies, generics maker Cipla is petitioning the country's government to revoke 5 patents for Novartis' respiratory drug Indacterol and is launching a low-cost version of the product to boost local access.


After strong Q3, no $55B deals in AbbVie's future, CEO says. But a smaller one? Maybe

No Shire? No problem for AbbVie. At least, for now.

Jobs saved as Boehringer Ingelheim finds Chinese buyer for U.S. plant set to close

About 240 workers at a Boehringer Ingelheim complex in Virginia will have something special to celebrate this Thanksgiving: the prospect of keeping their jobs. Just weeks ahead of closing the facility and laying off all its workers, Boehringer has found a Chinese buyer that intends to add to the headcount there.

Copaxone, still growing, helps Teva pass Q3 estimates

Sales of Teva's multiple sclerosis drug, Copaxone, are still growing--at least for now. The Israeli company's top-seller, whose patent is currently the subject of a Supreme Court appeal, ticked up 5% to reach $1.1 billion in Q3 sales.